DB
AXDX

Dmitry Balyasny’s Accelerate Diagnostics AXDX Stock Holding History

Dmitry Balyasny’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-38,047
Closed -$9.97M – 1930
2017
Q4 		$9.97M Buy
+38,047
New +$8.92M 0.03% 646

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.89B AUM 151.53% 1-Year Est. Return

Dmitry Balyasny's AXDX Position: Q1 2018 in Review

Dmitry Balyasny sold out of Accelerate Diagnostics (AXDX) in Q1 2018, closing a stake of 38,047 shares — an estimated $9.97M sold.

Dmitry Balyasny first reported a position in AXDX in Q4 2017 and held it in 1 quarter. The position peaked at $9.97M in Q4 2017. 116 funds tracked by Wall St. Rank hold AXDX as of Q1 2018.

  • Dmitry Balyasny reported no remaining Accelerate Diagnostics position as of Q1 2018 after selling out during the quarter.
  • Dmitry Balyasny sold 38,047 Accelerate Diagnostics shares in Q1 2018, an estimated $9.97M.
  • Dmitry Balyasny first reported a position in Accelerate Diagnostics in Q4 2017 and held it in 1 quarter.
  • Dmitry Balyasny's Accelerate Diagnostics position peaked at $9.97M in Q4 2017.
  • 116 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2018.

Based on Balyasny Asset Management's 13F filing for Q1 2018, filed 15 May 2018.